SCHEMBL3497972

SCHEMBL3497972

O=C(O)Cc1ccc(OCc2cccs2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.53
MAPT P10636 1/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
LTA4H P09960 1/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
HPGD P15428 1/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
TP53 P04637 1/20 0.47
KMT2A Q03164 1/20 0.47
FFAR1 O14842 2/20 0.46
ESR1 P03372 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
TRPM8 Q7Z2W7 1/20 0.45
RXRA P19793 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20319189 0.80 HPGD (0.50) POLBMAPTMAPK1SMN1; SMN2LTA4H
SCHEMBL6616525 0.78 TDP1 (0.51) MAPTSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL1680389 0.78 MAOB (0.54) POLBLTA4HHPGD
SCHEMBL1066614 0.77 FFAR1 (0.70) FFAR1CYP1A2CYP2C19
SCHEMBL4222632 0.76 FFAR1 (0.68) FFAR1CYP1A2CYP2C19
Hydrochloric Acid SCHEMBL10622121 0.76 FFAR1 (0.68) FFAR1CYP1A2CYP2C19
Ammonia Solution, Strong SCHEMBL27788257 0.76 FFAR1 (0.68) FFAR1CYP1A2CYP2C19
SCHEMBL8935261 0.75 POLB (0.47) POLBTSHRMAPK1SMN1; SMN2LTA4H
SCHEMBL6182 0.75 FFAR1 (0.69) MAPTTSHRNPC1RAB9AMEN1
SCHEMBL14539208 0.74 PTPRC (0.64) SMN1; SMN2RAB9ATP53FFAR1RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 POLB 4658/4885MAPT 4820/4885TSHR 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.